Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**10-hydroxy-2-decenoic acid** is a unique unsaturated fatty acid and the major lipid component of royal jelly, produced by honeybees. It is also known as queen bee acid. This compound exhibits a range of biological activities in vitro and in vivo, including anti-inflammatory, antimicrobial, antitumor, antiangiogenic, immunomodulatory, estrogen-like effects, neurogenic activity promoting neural stem cell differentiation, and inhibition of histone deacetylase activity. It has been shown to modulate cytokine production via NF-kB pathway inhibition and acts as an agonist at human TRPA1 and TRPV1 receptors. In animal models it accelerates gastric ulcer healing and increases collagen synthesis in skin fibroblasts[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 10-hydroxy-2-decenoic acid.